Abstract: Conjugate (KTAC) compounds that include a peptidic kappa opioid receptor agonist linked through a protease-sensitive linker and/or acid-sensitive linker to an antibody molecule are provided. The linker may include spacer regions on either side of the protease sensitive cleavage site. The antibody can be a monoclonal antibody such as a therapeutic monoclonal antibody. The KTAC compounds may be incorporated into pharmaceutical compositions useful for the treatment of diseases and conditions, particularly those that include an inflammatory component.

Abstract: The present invention provides isolated nucleic acid molecules encoding CRF2 receptors, recombinant expression vectors and host cells suitable for expressing such receptors, as well as compositions and methods which utilize such receptors.

Abstract: Disclosed herein are non-endogenous, constitutively activated forms of the human 5-HT2A and human 5-HT2C receptors and uses of such receptors to screen candidate compounds. Further disclosed herein are candidate compounds identified by the screening method which act at the 5HT2A receptors. Yet further disclosed is a new class of compounds which act at the 5HT2A receptors.